AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for CNS diseases, focusing on Alzheimer’s disease and pain, today announced today announced that the company will hold a live expert event on February 19 at 15:00 CET (09:00 am ET) with Professor Henrik Zetterberg as special expert guest speaker.
In the symposium, titled “Advances in the treatment of Alzheimer’s disease – Small molecule gamma-secretase modulators (GSMs) as promising disease-modifying treatments”, Professor Zetterberg will provide an overview of cutting-edge science in the Alzheimer’s disease, with a focus on recent developments in the therapeutic and diagnostic areas. Professor Zetterberg will be joined by AlzeCure’s CEO, Martin Jönsson, and CSO, Johan Sandin, who will also discuss the company’s progress in the development of potentially disease-modifying treatments for Alzheimer’s disease and other CNS disorders.
AlzeCure’s Alzstatin platform consists of potent and selective GSMs that have been shown to reduce the production of toxic Aβ42 oligomers by more than 60% in preclinical models of Alzheimer’s disease, without impacting other signalling pathways controlled by gamma-secretase, a major limitation of first-generation gamma-secretase inhibitors (GSIs). AlzeCure’s GSMs concurrently increase the production of Aβ37 and Aβ38, which have shown protective properties by preventing Aβ aggregation. The Alzstatin program will benefit from the clinical development path being layed out by Roche which also has a GSM in development, RG6289, demonstrating big pharma validation and interest in the mechanism. At the recent CTAD conference, Roche presented phase I clinical data for RG6289, showing proof-of-mechanism and a good safety profile.
AlzeCure’s NeuroRestore (Trk-PAM) program is designed to improve cognition in Alzheimer’s disease and other CNS disorders, with data also suggesting potential disease-modifying effects. The program has demonstrated a good safety profile and target engagement in phase I and is in preparation for phase II studies.
Agenda
15:00 – Welcome address, agenda & company overview – Martin Jönsson, CEO, AlzeCure
15:10 – Alzheimer’s disease and the amyloid hypothesis – Henrik Zetterberg, MD, PhD, Gothenburg University. & University College London
15:50 – Alzstatin: a small molecule disease modifying and preventive therapy against Alzheimer’s – Johan Sandin, PhD, CSO, AlzeCure
16:05 – Q&A
16:25 – Concluding remarks – Martin Jönsson, CEO, AlzeCure
The event is in collaboration with Finwire, requires no pre-registration and can be followed via: https://www.finwire.tv/webcast/alzecure-pharma/capital-market-day/
The presentation will also be available afterwards on AlzeCure’s website https://www.alzecurepharma.se/en/presentations-and-interviews/ as well at AlzeCure’s YouTube channel: https://www.youtube.com/@alzecurepharma5138
